Skip to main content

Table 3 Cumulative incidence of revision at 1 and 5 years’ follow-up and effect of comorbidities from the Elixhauser index on the risk of revision in Total Knee Arthroplasty (TKA)

From: Impact of comorbidity on the short- and medium-term risk of revision in total hip and knee arthroplasty

  1 year follow-up 5 years’ follow-up
np nr incidence (95% CI) SHR (95%CI) p value np nr incidence (95% CI) SHR (95% CI) p value
Burden of comorbidity      0.008      0.403
 0 comorbidities 13,139 107 0.77 (0.63–0.92) 1.00   7532 333 3.74 (3.40–4.10) 1.00  
 1 comorbidity 15,838 142 0.84 (0.71–0.99) 1.18 (0.93–1.53)   8533 355 3.48 (3.18–3.79) 1.04 (0.92–1.19)  
 > =2 comorbidities 15,465 164 0.97 (0.83–1.13) 1.39 (1.09–1.78)   7505 321 3.47 (3.17–3.79) 1.06 (0.93–1.20)  
Uncomplicated hypertension 24,118 228 0.88 (0.77–1.00) 1.13 (0.93–1.37) 0.214 12,479 511 3.38 (3.14–3.63) 1.03 (0.93–1.15) 0.549
Uncomplicated diabetes 7005 60 0.79 (0.61–1.01) 0.92 (0.70–1.21) 0.541 3556 139 3.17 (2.74–3.62) 0.91 (0.78–1.06) 0.216
Obesity 4649 66 1.29 (1.00–1.63) 1.53 (1.17–1.99) 0.002 2329 94 3.78 (3.22–4.40) 0.97 (0.82–1.14) 0.711
Depression 4171 39 0.87 (0.63–1.17) 1.08 (0.77–1.51) 0.651 1929 101 3.93 (3.30–4.61) 1.06 (0.89–1.27) 0.484
Chronic pulmonary disease 3624 32 0.82 (0.57–1.14) 0.95 (0.66–1.36) 0.783 1795 76 3.25 (2.68–3.90) 1.01 (0.83–1.23) 0.933
Hypothyroidism 2524 24 0.85 (0.56–1.24) 1.12 (0.73–1.71) 0.603 1152 58 3.78 (3.02–4.67) 1.04 (0.83–1.30) 0.724
Deficiency anemia 990 17 1.58 (0.96–4.46) 1.92 (1.18–3.11) 0.008 457 15 3.34 (2.32–4.65) 1.09 (0.77–1.56) 0.615
Renal failure 775 9 1.02 (0.51–1.88) 1.25 (0.64–2.42) 0.515 262 9 2.40 (1.46–3.72) 0.98 (0.61–1.57) 0.938
Hypertension with complications 758 9 1.03 (0.511.89) 1.35 (0.70–2.61) 0.376 256 8 2.38 (1.41–3.75) 0.94 (0.58–1.53) 0.815
Valvular disease 745 10 1.19 (0.61–2.11) 1.61 (0.85–3.03) 0.144 365 9 2.66 (1.64–4.07) 0.94 (0.60–1.49) 0.803
Rheumatoid arthritis 572 8 1.27 (0.60–2.39) 1.37 (0.68–2.78) 0.379 235 10 3.65 (2.20–5.65) 0.90 (0.57–1.44) 0.673
Other neurological disorders 625 7 1.04 (0.47–2.06) 1.23 (0.58–2.59) 0.590 313 12 3.19 (1.98–4.85) 1.01 (0.64–1.60) 0.951
Liver disease 563 15 2.29 (1.34–3.66) 2.50 (1.49–4.20) 0.001 257 16 5.51 (3.81–7.66) 1.60 (1.11–2.29) 0.011
Congestive heart failure 432 3 0.66 (0.18–1.80) 0.88 (0.28–2.74) 0.882 226 5 2.00 (0.94–3.78) 0.70 (0.35–1.39) 0.306
Peripheral vascular disorders 338 4 1.11 (0.37–2.67) 1.35 (0.51–3.62) 0.545 198 7 3.62 (1.90–6.21) 1.16 (0.64–2.09) 0.626
Solid tumor 204 1 0.49 (0.05–2.50) 0.53 (0.08–3.79) 0.530 87 1 1.20 (0.23–3.97) 0.38 (0.10–1.57) 0.187
Diabetes with complications 191 2 0.97 (0.19–3.20) 1.08 (0.27–4.34) 0.911 78 8 5.71 (2.91–9.86) 1.82 (0.98–3.38) 0.057
Coagulopathy 190 2 0.93 (0.19–3.06) 1.10 (0.27–4.42) 0.896 85 1 1.46 (0.40–3.92) 0.53 (0.17–1.67) 0.280
Blood loss anemia 201 2 0.93 (0.19–3.07) 0.75 (0.19–3.12) 0.709 96 10 6.56 (3.56–10.80) 1.54 (0.87–2.77) 0.141
Fluid and electrolyte disorders 184 1 0.50 (0.05–2.58) 0.57 (0.08–4.12) 0.575 62 4 2.73 (1.03–5.89) 0.91 (0.37–2.18) 0.841
Alcohol abuse 171 2 1.07 (0.21–3.52) 0.85 (0.21–3.48) 0.827 76 4 3.79 (1.54–7.69) 0.91 (0.37–2.23) 0.841
Psychosis 155 0 NR NC NC 54 3 2.49 (0.67–6.58) 0.60 (0.19–1.86) 0.378
Paralysis 79 2 2.36 (0.45–7.42) 2.67 (0.76–10.78) 0.169 31 5 11.79 (4.98–21.78) 3.14 (1.49–6.60) 0.003
Pulmonary circulation disorders 58 1 1.41 (0.12–6.72) 1.87 (0.26–13.46) 0.533 27 1 3.09 (0.58–9.58) 1.05 (0.25–4.30) 0.951
Lymphoma 31 0 NR NC NC 12 1 3.49 (0.26–15.09) 1.16 (0.17–8.10) 0.881
Peptic ulcer disease 28 1 3.57 (0.26–15.41) 3.25 (0.45–23.51) 0.243 16 0 NR NC NC
Drug abuse 10 0 NR NC NC 3 0 NR NC NC
Metastatic cancer 9 0 NR NC NC 3 0 NR NC NC
Weight loss 8 0 NR NC NC 6 1 11.11 (0.6–38.77) 3.32 (0.46–23.81) 0.232
AIDS 4 0 NR NC NC 1 0 NR NC NC
  1. np number of primary procedures at 1 and 5 years’ follow-up, nr number of revision procedures since the primary operation (from the beginning to 1 year and from 1 year to 5 years, at follow-up), SHR Subhazard ratio from competing risks models adjusted for sex, age, year of intervention, fixation type and type of hospital, NR no revisions undergone from 1 to 5 years’ follow-up, NC Not calculable
  2. Incidence (95%CI): cumulative incidence of revision considering patient death as a competing event and the 95% Confidence Interval
  3. Variance inflation tests < 4 for all models